查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1933871

微創肥胖症治療市場：按類型、技術、最終用戶和分銷管道分類的全球預測（2026-2032年）

Minimally Invasive Surgery for Obesity Management Market by Type, Technology, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年，用於肥胖症管理的微創手術市場價值為 20.8 億美元，預計到 2026 年將成長至 22.9 億美元，年複合成長率為 9.45%，到 2032 年將達到 39.2 億美元。

關鍵市場統計數據
基準年 2025 20.8億美元
預計年份：2026年 22.9億美元
預測年份 2032 39.2億美元
複合年成長率 (%) 9.45%

針對微創減重手術的策略方法，重點在於臨床促進因素、醫療設備創新以及現代醫學中不斷發展的照護路徑。

微創手術在肥胖症治療領域已從小眾技術發展成為主流臨床路徑，融合了手術精準性、醫療設備創新和多學科患者照護。在肥胖症盛行率不斷上升以及對改善手術全期期預後日益重視的推動下，包括內視鏡手術、腹腔鏡手術和機器人輔助技術在內的微創方法正在重塑臨床醫生、醫院和門診手術中心開展永續減重干預的方式。隨著患者越來越尋求治療方法，臨床醫生正透過拓展手術選擇、引入新的手術平台和完善選擇標準來積極應對這一需求。

技術成熟度、分散式護理路徑和以價值為導向的支付方趨勢如何融合，從而重塑微創減肥手術的採用和提供方式

近年來，一系列變革性變化正在改變肥胖症治療的模式，並推動微創手術的發展趨勢。內視鏡和機器人技術的成熟使得手術創傷更小、可重複性更高，從而擴大了適應症範圍並降低了手術全期併發症。內視鏡技術已從臨時性手術發展為更持久的代謝干預，而機器人平台則提高了複雜腹腔鏡重組手術的人體工學性能和精準度，迫使外科醫生重新評估其手術選擇和培訓重點。

評估2025年關稅變化將如何影響醫療設備貿易，進而改變微創肥胖治療的供應鏈、採購慣例和市場進入動態。

將於2025年生效的跨境貿易政策措施可能會對微創肥胖症治療用外科器械的採購和分銷造成重大阻礙。無論關稅是選擇性地針對特定醫療設備類別，還是整體應用於醫療進口，都將造成成本波動，供應商和醫療機構都必須適應這種波動。對於依賴全球生產網路的製造商而言，關稅負擔的增加可能會壓縮短期利潤率，延遲產品上市，並促使其重新評估籌資策略。因此，醫院和門診中心可能面臨更高的資本設備和一次性耗材購買成本，這可能會影響採購速度，並使擁有整體擁有成本（TCO）優勢的供應商受益。

以細分市場為中心，分析手術類型、平台級技術、臨床環境和通路，以識別臨床應用和商業性契合度。

深入分析市場細分，可以發現不同手術類型、技術平台、臨床環境和通路之間存在不同的臨床和商業性動態。在手術類別中，胃束帶術、改良胃繞道手術、袖狀胃切除術和胃內球囊治療是主要分類，其重要細分包括：胃束帶術包括腹腔鏡可調節式和微創式；胃旁路術包括迷你胃旁路術和Roux-en-Y胃旁路術；袖狀胃切除術包括內鏡下袖狀胃成形術和Roux-en-Y胃旁路術；袖狀胃內球囊切除術包括內鏡下袖狀胃成形術和下球囊狀置入術和內口服型術。每種手術都有其自身的學習曲線、實證依據和患者選擇標準，這些因素都會影響外科醫師的選擇和醫療機構提供的服務。

區域比較分析突顯了美洲、歐洲、中東和非洲以及亞太地區在採用率、報銷解讀和供應鏈考量方面的差異。

區域趨勢對臨床應用、報銷架構和供應鏈韌性有顯著影響。在美洲，成熟的醫療保健體系和完善的減重手術計畫與日益成長的微創治療需求並存，這些微創治療方案旨在縮短住院時間並最佳化治療效率。私人保險和混合報銷機制促進了以器械為中心的創新和商業性夥伴關係，而州和聯邦政策討論則影響著醫療服務的可及性和合格標準。歐洲、中東和非洲的區域差異則更為明顯。西方醫療保健體系強調療效比較證據和集中式衛生技術評估（HTA）流程，而中東和非洲部分地區則透過公私合營，投資於能力建設和基礎設施建設，以擴大外科和內視鏡減肥手術的可及性。

競爭格局概述：重點在於產品差異化、實證商業化和策略聯盟，以加速臨床應用和市場擴張。

微創減重手術領域的競爭格局取決於產品廣度、臨床證據、培訓和服務能力以及策略夥伴關係關係。領先企業透過投資平台互通性、差異化耗材以及整合設備、培訓和臨床支援的捆綁式服務來實現差異化。監管核准和上市後監測在商業性發展中起著至關重要的作用。積極產生真實世界數據並與支付相關人員合作以證明長期效益的公司通常能夠獲得更永續的商業性發展軌跡。

製造商、供應商和經銷商行動指南：加強證據、降低供應鏈風險並促進在不同臨床環境中的應用

產業領導者應採取一系列切實可行的措施，將洞見轉化為快速實施和穩健的商業模式。首先，應優先產生高品質的臨床和經濟證據，以解答支付方的疑問並幫助最佳化治療路徑。前瞻性註冊研究、可操作的結果研究和成本分析對於確保報銷和機構採納至關重要。其次，應透過區域製造地多元化、關鍵零件的多通路採購以及策略性庫存管理來實現供應鏈多元化，從而降低關稅和物流中斷的風險，同時在經濟可行的情況下評估近岸外包的可能性。

採用透明且可重複的研究途徑，結合一手臨床訪談、供應商評估和二手檢驗，以檢驗策略性發現及其限制。

這些研究結果背後的調查方法結合了初步的質性檢驗，以確保其相關性和可靠性。初步數據包括對執業減重外科醫生和內視鏡外科醫生、醫院和門診中心臨床計畫主任、供應鏈和採購人員以及支付方和報銷專業人員的結構化訪談。與這些相關人員的對話主要圍繞著臨床偏好、手術流程、培訓和資格認證需求、採購決策因素以及他們認為的推廣障礙。二次檢驗則利用監管文件、臨床試驗註冊資訊、同儕審查的臨床文獻和公共文件，對初步訪談中出現的趨勢和主題進行交叉檢驗和強化。

最終整合臨床、商業性和政策促進因素，以確定微創肥胖治療的發展方向和相關人員的策略要務。

簡而言之，微創肥胖治療方法正處於一個轉折點，技術創新、醫療服務模式的變革以及支付方期望的轉變在此交匯融合。從胃束帶和胃繞道手術的各種變體到袖狀胃切除術和胃內球囊，再到內視鏡、腹腔鏡和機器人手術平台，多種多樣的手術選擇為臨床醫生、製造商和採購商帶來了機會和挑戰。報銷、監管途徑和手術能力方面的區域差異凸顯了製定本地化策略的必要性，而影響貿易和採購的政策措施則可能對醫療設備的供應和價格趨勢產生重大影響。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 微創肥胖症手術市場（按類型分類）

  • 胃束帶
    • 腹腔鏡可調節
    • 微創
  • 胃繞道手術
    • 迷你胃繞道手術
    • 盧安懷
  • 胃袖切除術
    • 內視鏡袖狀胃成形術
    • 腹腔鏡袖狀切除術
  • 胃內球囊
    • 內視鏡球囊
    • 可吞嚥氣球

9. 按技術分類的微創肥胖症管理手術市場

  • 內視鏡
    • 氣球
    • 胃鏡
  • 腹腔鏡手術
    • 能量裝置
    • 手持式儀器
    • 訂書機
  • 機器人輔助
    • 配件
    • 系統

10. 以最終用戶分類的肥胖症微創手術市場

  • 門診手術中心
  • 醫院
  • 專科診所

11. 微創肥胖症管理手術市場（依通路分類）

  • 直銷
    • 場力
    • 機構競標
  • 線上銷售
    • 公司網站
    • 電子商務平台
  • 第三方經銷商
    • 國內的
    • 國際的

12. 各地區微創肥胖症手術市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

13. 微創肥胖症手術市場（以群體分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國微創肥胖症手術市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

15. 美國微創肥胖症管理手術市場

16. 中國微創肥胖症手術市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Allurion Technologies, Inc.
  • Apollo Endosurgery, Inc.
  • Aspire Bariatrics Ltd.
  • B. Braun Melsungen AG
  • Bariatric Solutions GmbH
  • Boston Scientific Corporation
  • Conmed Corporation
  • Cousin Biotech
  • EndoGastric Solutions, Inc.
  • EndoSphere, Inc.
  • GI Dynamics, Inc.
  • Hologic, Inc.
  • Intuitive Surgical, Inc.
  • Johnson & Johnson Services, Inc.
  • Karl Storz SE & Co. KG
  • Mediflex Surgical Products
  • Medtronic, Inc.
  • Obalon Therapeutics, Inc.
  • Olympus Corporation
  • ReShape Lifesciences, Inc.
  • Smith & Nephew
  • Spatz Medical, Inc.
  • Stryker Corporation
  • TransEnterix
  • USGI Medical, Inc.
  • WL Gore & Associates, Inc.
Product Code: MRR-C36616F69995

The Minimally Invasive Surgery for Obesity Management Market was valued at USD 2.08 billion in 2025 and is projected to grow to USD 2.29 billion in 2026, with a CAGR of 9.45%, reaching USD 3.92 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.08 billion
Estimated Year [2026] USD 2.29 billion
Forecast Year [2032] USD 3.92 billion
CAGR (%) 9.45%

A strategic orientation to minimally invasive obesity surgeries highlighting clinical drivers, device innovation, and care pathway evolution in contemporary practice

Minimally invasive surgery for obesity management has evolved from a niche set of techniques into a mainstream clinical pathway that integrates surgical precision, device innovation, and multidisciplinary patient care. Driven by rising prevalence of obesity and a simultaneous emphasis on improving perioperative outcomes, minimally invasive approaches such as endoscopic procedures, laparoscopic operations, and robotic-assisted techniques are reshaping how clinicians, hospitals, and ambulatory surgical centers approach durable weight-loss interventions. Patients increasingly seek therapies that minimize recovery time and procedural risk while preserving long-term metabolic benefit, and clinicians are responding by expanding procedural portfolios, adopting new platforms, and refining selection criteria.

As a consequence, the ecosystem around obesity surgery is maturing. Medical device manufacturers are investing in procedure-specific instruments, energy devices, stapling systems, endoscopic technologies, and robotics to support reproducible, efficient workflows. Parallel to hardware innovation, payers and health systems are revisiting reimbursement paradigms and pathway optimization to align incentives with value-based outcomes. Training and credentialing programs are adapting to accommodate a broader set of minimally invasive skillsets. Taken together, these dynamics are accelerating clinical adoption while raising the bar for evidence generation, supply-chain reliability, and multidisciplinary care coordination.

How technological maturation, decentralized care pathways, and value-focused payer dynamics are converging to reshape adoption and delivery of minimally invasive bariatric treatments

Recent years have witnessed several transformative shifts that are altering the trajectory of obesity care delivery and the adoption of minimally invasive procedures. Technological maturation in endoscopy and robotics is enabling less invasive, more reproducible interventions that expand candidacy and reduce perioperative morbidity. Endoscopic techniques are moving beyond temporary measures to more durable metabolic interventions, while robotic platforms are enhancing ergonomics and precision for complex laparoscopic reconstructions, prompting surgeons to re-evaluate procedure selection and training priorities.

Concurrently, care pathways are decentralizing as ambulatory surgical centers and specialized clinics take on a larger share of elective bariatric procedures, enabled by standardized protocols and enhanced recovery after surgery frameworks. Payers are increasingly focused on outcomes, prompting bundled-payment pilots and condition-based contracting that reward sustained weight-loss and downstream cost reduction. Patient expectations are shifting toward shorter hospital stays, minimally disruptive approaches, and integrated digital follow-up, which is catalyzing investment in remote monitoring and telehealth-enabled pre- and post-operative care. Supply chain consolidation and partnerships between device makers and providers are emerging as commercially pragmatic responses to pricing pressure, regulatory complexity, and the need for comprehensive training and service models. These shifts collectively favor agile organizations that can align clinical evidence, operational scalability, and patient-centric delivery models.

Assessment of how tariff shifts affecting medical device trade in 2025 could alter supply chains, procurement practices, and access dynamics for minimally invasive obesity therapies

Policy actions affecting cross-border trade in 2025 have the potential to create material friction in the procurement and distribution of surgical equipment used in minimally invasive obesity management. Tariffs, whether applied selectively to device categories or broadly across medical imports, introduce cost volatility that suppliers and providers must manage. For manufacturers that rely on globalized production networks, elevated tariff burdens can prompt near-term margin compression, delayed product launches, and a reassessment of sourcing strategies. In turn, hospitals and ambulatory centers may encounter higher acquisition costs for capital equipment and single-use consumables, which can influence purchasing cadence and favor suppliers that demonstrate total-cost-of-ownership advantages.

Beyond direct cost impacts, tariffs can drive strategic responses that reshape the market. Manufacturers may accelerate localization initiatives, invest in regional manufacturing capacity, or reconfigure bill-of-materials to minimize tariff exposure. Procurement teams may shift toward longer-term contracts, consignment models, or multi-supplier strategies to ensure continuity of supply and predictable budgeting. Equity in access becomes a central concern if increased landed costs are passed on to providers and ultimately to patients through higher procedural fees or constrained program expansion. Finally, regulatory and compliance complexity can increase as importers navigate classification, valuation, and exemption processes, requiring closer collaboration between commercial, legal, and supply-chain functions to mitigate operational risk and preserve patient access to innovative minimally invasive therapies.

Segment-centered insights that dissect procedural subtypes, platform-level technologies, care settings, and distribution pathways to illuminate clinical adoption and commercial fit

A nuanced view of segmentation reveals distinct clinical and commercial dynamics across procedure types, technology platforms, care settings, and distribution pathways. Procedurally, the landscape encompasses gastric band approaches, gastric bypass variants, gastric sleeve techniques, and intragastric balloon therapies, with important sub-distinctions: gastric banding includes laparoscopic adjustable and minimally invasive iterations, gastric bypass options cover mini gastric bypass and Roux-en-Y configurations, gastric sleeve care pathways include endoscopic sleeve gastroplasty as well as laparoscopic sleeve gastrectomy, and intragastric balloon solutions span endoscopic balloon placements and emerging swallowable balloon systems. Each procedural family follows its own learning curve, evidence base, and patient selection criteria, influencing surgeon preference and institutional offering.

From a technology perspective, endoscopic, laparoscopic, and robotic-assisted platforms are central to service delivery. Endoscopic technologies further break down into balloons and gastroscopes that support transoral interventions, laparoscopic approaches rely on energy devices, handheld instruments, and staplers to enable tissue manipulation and resection, and robotic-assisted solutions comprise systems and accessories that augment control and visualization. End users differ in operational emphasis and throughput, with ambulatory surgical centers focusing on efficiency and rapid turnover, hospitals integrating multidisciplinary perioperative care often for complex cases, and specialty clinics offering focused pathways for assessment and longitudinal follow-up. Distribution channels shape commercial access and service models as direct sales operate through field force and institutional tenders, online sales occur through company websites and B2C e-commerce platforms, and third-party distributors manage domestic and international logistics and aftersales support. Understanding the interplay of these segments is essential for aligning product design, training programs, and go-to-market strategies with the clinical workflows and procurement preferences of each stakeholder group.

Regional comparative intelligence highlighting how the Americas, EMEA, and Asia-Pacific diverge in adoption, reimbursement interpretation, and supply chain considerations

Regional dynamics materially influence clinical adoption, reimbursement frameworks, and supply-chain resilience. In the Americas, mature systems and established bariatric programs coexist with rising demand for minimally invasive options that reduce length of stay and optimize throughput; private-pay and mixed reimbursement environments encourage device-focused innovation and commercial partnerships, while state and federal policy debates shape access and eligibility criteria. Across Europe, the Middle East & Africa, heterogeneity is pronounced: Western European health systems emphasize comparative-effectiveness evidence and centralized HTA processes, while parts of the Middle East and Africa are investing in capacity building and infrastructure to expand access to surgical and endoscopic obesity care, often through public-private collaborations.

Asia-Pacific exhibits diverse adoption curves driven by demographic trends, surgical capacity expansion, and localized manufacturing ecosystems. Several markets in the region are rapidly scaling training programs and investing in robotic and endoscopic platforms, driven by both clinical demand and strategic investments in medtech manufacturing. Cross-border supply relationships and regional regulatory harmonization efforts are increasingly important for manufacturers seeking streamlined market entry. Each region requires tailored commercial strategies that accommodate differences in payer architecture, clinician training, regulatory timelines, and procurement behavior, and firms that adapt product configurations, training models, and pricing approaches to local contexts will be better positioned to gain traction.

Competitive landscape overview emphasizing product differentiation, evidence-led commercialization, and strategic partnerships that accelerate clinical adoption and market reach

Competitive dynamics in the minimally invasive obesity surgery ecosystem are shaped by product breadth, clinical evidence, training and service capabilities, and strategic partnerships. Leading participants are differentiating through investments in platform interoperability, differentiated consumables, and bundled service offerings that combine devices, training, and clinical support. Regulatory approvals and post-market surveillance play a decisive role in commercial momentum; companies that proactively generate real-world outcomes and engage with payer stakeholders to demonstrate long-term benefit typically secure a more sustainable commercial trajectory.

Strategic activity also includes alliance formation with hospitals, ambulatory networks, and academic centers to support adoption and credentialing, as well as distribution partnerships that extend geographic reach while managing local regulatory and logistic complexity. Mergers and acquisitions remain a route to rapidly augment portfolio capabilities, particularly in areas such as endoscopic systems, energy devices, and surgical robotics. To remain competitive, companies are prioritizing evidence generation, clinician education programs, and service models that lower the total cost of adoption for hospitals and outpatient facilities, while ensuring that supply continuity and localized support are available in priority markets.

Action-oriented playbook for manufacturers, providers, and distributors to strengthen evidence, de-risk supply chains, and fast-track adoption across diverse care settings

Industry leaders should pursue a set of pragmatic actions to translate insights into accelerated adoption and resilient commercial models. First, prioritize generation of high-quality clinical and economic evidence that addresses payer questions and informs pathway optimization; prospective registries, pragmatic outcome studies, and cost-of-care analyses will be critical to secure reimbursement and institutional adoption. Second, diversify supply chains by combining regional manufacturing, dual-sourcing of critical components, and strategic inventory management to mitigate tariff and logistical disruption risks, while evaluating near-shoring where economically viable.

Third, tailor commercial and training models to the needs of distinct end users: develop fast-track adoption packages for ambulatory surgical centers that emphasize efficiency and disposable kits, while offering comprehensive training and perioperative protocols for hospitals handling complex cases. Fourth, engage early with payers and health-system purchasers to pilot bundled payment models and performance-based contracting that tie reimbursement to patient-centered outcomes. Fifth, invest in digital patient pathways, remote monitoring, and telehealth-enabled follow-up to improve adherence and capture real-world outcomes. Finally, pursue targeted partnerships or licensing arrangements that expand geographic presence or complement core capabilities without incurring prohibitive fixed costs, and maintain an agile pricing strategy that reflects total cost of ownership and value delivered.

Transparent and reproducible research approach combining primary clinical interviews, supplier assessments, and secondary verification to validate strategic insights and limitations

The research methodology underpinning these insights integrates primary qualitative engagement and rigorous secondary verification to ensure relevance and credibility. Primary inputs include structured interviews with practicing bariatric and endoscopic surgeons, clinical program directors in hospitals and ambulatory centers, supply-chain and procurement leaders, and payer and reimbursement specialists. These stakeholder conversations focus on clinical preferences, procedure-level workflows, training and credentialing needs, procurement decision drivers, and perceived barriers to adoption. Secondary validation draws on regulatory filings, clinical trial registries, peer-reviewed clinical literature, and public policy documents to cross-check trends and corroborate themes emerging from primary interviews.

Analytical rigor is achieved through triangulation of data sources and iterative synthesis. Procedural categorizations and technology taxonomies are validated against clinician feedback, while commercial and distribution dynamics are cross-referenced with supplier disclosures and procurement case studies. Limitations are acknowledged: the analysis emphasizes qualitative drivers and strategic implications rather than numerical market sizing, and findings may evolve as new clinical evidence, regulatory decisions, or policy measures emerge. To address this, recommended follow-up includes periodic updates and bespoke deep dives tailored to specific geographies, procedure subtypes, or technology segments.

Final synthesis of clinical, commercial, and policy drivers that converge to determine the trajectory of minimally invasive bariatric care and strategic imperatives for stakeholders

In sum, minimally invasive approaches to obesity management are at an inflection point where technological innovation, shifting care delivery models, and evolving payer expectations converge. The diversity of procedural options-from gastric band and bypass variations to sleeve procedures and intragastric balloons-paired with endoscopic, laparoscopic, and robotic platforms, creates both opportunity and complexity for clinicians, manufacturers, and purchasers. Regional variation in reimbursement, regulatory pathways, and surgical capacity underscores the need for localized strategies, while policy actions affecting trade and procurement can materially influence device availability and pricing dynamics.

Stakeholders who succeed will be those that align robust clinical evidence with pragmatic commercialization and supply strategies, invest in scalable training and service models, and collaborate closely with payers and providers to demonstrate value. By focusing on adaptability, evidence generation, and patient-centric pathways, clinical programs and industry participants can expand access to minimally invasive obesity treatments while maintaining quality and financial sustainability.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Minimally Invasive Surgery for Obesity Management Market, by Type

  • 8.1. Gastric Band
    • 8.1.1. Laparoscopic Adjustable
    • 8.1.2. Minimally Invasive
  • 8.2. Gastric Bypass
    • 8.2.1. Mini Gastric Bypass
    • 8.2.2. Roux-En-Y
  • 8.3. Gastric Sleeve
    • 8.3.1. Endoscopic Sleeve Gastroplasty
    • 8.3.2. Laparoscopic Sleeve Gastrectomy
  • 8.4. Intragastric Balloon
    • 8.4.1. Endoscopic Balloon
    • 8.4.2. Swallowable Balloon

9. Minimally Invasive Surgery for Obesity Management Market, by Technology

  • 9.1. Endoscopic
    • 9.1.1. Balloons
    • 9.1.2. Gastroscopes
  • 9.2. Laparoscopic
    • 9.2.1. Energy Devices
    • 9.2.2. Handheld Instruments
    • 9.2.3. Staplers
  • 9.3. Robotic Assisted
    • 9.3.1. Accessories
    • 9.3.2. Systems

10. Minimally Invasive Surgery for Obesity Management Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Hospitals
  • 10.3. Specialty Clinics

11. Minimally Invasive Surgery for Obesity Management Market, by Distribution Channel

  • 11.1. Direct Sales
    • 11.1.1. Field Force
    • 11.1.2. Institutional Tender
  • 11.2. Online Sales
    • 11.2.1. Company Website
    • 11.2.2. E-Commerce Platforms
  • 11.3. Third Party Distributors
    • 11.3.1. Domestic
    • 11.3.2. International

12. Minimally Invasive Surgery for Obesity Management Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Minimally Invasive Surgery for Obesity Management Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Minimally Invasive Surgery for Obesity Management Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Minimally Invasive Surgery for Obesity Management Market

16. China Minimally Invasive Surgery for Obesity Management Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Allurion Technologies, Inc.
  • 17.6. Apollo Endosurgery, Inc.
  • 17.7. Aspire Bariatrics Ltd.
  • 17.8. B. Braun Melsungen AG
  • 17.9. Bariatric Solutions GmbH
  • 17.10. Boston Scientific Corporation
  • 17.11. Conmed Corporation
  • 17.12. Cousin Biotech
  • 17.13. EndoGastric Solutions, Inc.
  • 17.14. EndoSphere, Inc.
  • 17.15. GI Dynamics, Inc.
  • 17.16. Hologic, Inc.
  • 17.17. Intuitive Surgical, Inc.
  • 17.18. Johnson & Johnson Services, Inc.
  • 17.19. Karl Storz SE & Co. KG
  • 17.20. Mediflex Surgical Products
  • 17.21. Medtronic, Inc.
  • 17.22. Obalon Therapeutics, Inc.
  • 17.23. Olympus Corporation
  • 17.24. ReShape Lifesciences, Inc.
  • 17.25. Smith & Nephew
  • 17.26. Spatz Medical, Inc.
  • 17.27. Stryker Corporation
  • 17.28. TransEnterix
  • 17.29. USGI Medical, Inc.
  • 17.30. W. L. Gore & Associates, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BAND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BAND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BAND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BAND, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC ADJUSTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC ADJUSTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC ADJUSTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY MINIMALLY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY MINIMALLY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BYPASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BYPASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BYPASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BYPASS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY MINI GASTRIC BYPASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY MINI GASTRIC BYPASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY MINI GASTRIC BYPASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ROUX-EN-Y, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ROUX-EN-Y, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ROUX-EN-Y, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC SLEEVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC SLEEVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC SLEEVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC SLEEVE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC SLEEVE GASTRECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC SLEEVE GASTRECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC SLEEVE GASTRECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INTRAGASTRIC BALLOON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INTRAGASTRIC BALLOON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INTRAGASTRIC BALLOON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC BALLOON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC BALLOON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC BALLOON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY SWALLOWABLE BALLOON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY SWALLOWABLE BALLOON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY SWALLOWABLE BALLOON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTROSCOPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTROSCOPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTROSCOPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENERGY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENERGY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENERGY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY HANDHELD INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY HANDHELD INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY HANDHELD INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY STAPLERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY STAPLERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY STAPLERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ROBOTIC ASSISTED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ROBOTIC ASSISTED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ROBOTIC ASSISTED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ROBOTIC ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ACCESSORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ACCESSORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ACCESSORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY FIELD FORCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY FIELD FORCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY FIELD FORCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INSTITUTIONAL TENDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INSTITUTIONAL TENDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INSTITUTIONAL TENDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ONLINE SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ONLINE SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ONLINE SALES, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY COMPANY WEBSITE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY COMPANY WEBSITE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY COMPANY WEBSITE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY E-COMMERCE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY E-COMMERCE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY E-COMMERCE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DOMESTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DOMESTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DOMESTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INTERNATIONAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INTERNATIONAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INTERNATIONAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BAND, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BYPASS, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC SLEEVE, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ROBOTIC ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ONLINE SALES, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BAND, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BYPASS, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC SLEEVE, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ROBOTIC ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ONLINE SALES, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BAND, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BYPASS, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC SLEEVE, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ROBOTIC ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ONLINE SALES, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BAND, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BYPASS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC SLEEVE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ROBOTIC ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ONLINE SALES, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BAND, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BYPASS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC SLEEVE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ROBOTIC ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ONLINE SALES, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BAND, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BYPASS, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC SLEEVE, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ROBOTIC ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ONLINE SALES, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BAND, 2018-2032 (USD MILLION)
  • TABLE 212. AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BYPASS, 2018-2032 (USD MILLION)
  • TABLE 213. AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC SLEEVE, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ROBOTIC ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ONLINE SALES, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BAND, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BYPASS, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC SLEEVE, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ROBOTIC ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY DIRECT SALES, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ONLINE SALES, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY THIRD PARTY DISTRIBUTORS, 2018-2032 (USD MILLION)
  • TABLE 239. GLOBAL MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BAND, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC BYPASS, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY GASTRIC SLEEVE, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY INTRAGASTRIC BALLOON, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ENDOSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY LAPAROSCOPIC, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY ROBOTIC ASSISTED, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN MINIMALLY INVASIVE SURGERY FOR OBESITY MANAGEMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN MINIMALLY INVASIVE SURGERY